<div id="readability-page-1"><div>(TheNewswire)Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (FSE: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it was unable to file its annualfinancial statements, management’s discussion and analysis and therequired certifications for the year ended October 31, 2025 (the“Annual Filings”) on or before the prescribed filing deadline of February28, 2026 (the “Annual FilingDeadline”).The Company and the auditor have been diligentlyworking to complete the Annual Filings, however, the Company was notable to make the required filings by the Annual Filing Deadline. Theprimary contributing factor to the delay was a late start to the auditas a result of the Company making changes to its accounting systemsand processes. The Company believes that the audit will be completedby April 28, 2026, with the annual filings to be completed as soon aspossible thereafter.As a result, the Company filed an application to theBritish Columbia Securities Commission to approve a temporarymanagement cease trade order (“MCTO”) under National Policy 12-203 –Management Cease Trade Orders (“NP 12-203”). TheMCTO was granted, effective March 3, 2026 prohibiting trading insecurities of the Company by the Chief Executive Officer of theCompany, James Passin, and Chief Financial Officer of the Company,Christopher Cherry.The Company expects to file the Annual Filings by April28, 2026. The MCTO will be in effect until the Annual Filings arefiled. The Company confirms that it will comply with the alternativeinformation guidelines required by NP 12-203 so long as the AnnualFilings are outstanding. The guidelines, amongother things, require the Company to issue bi-weekly default statusreports, in the form of news releases, for so long as the AnnualFilings have not been filed.About BioVaxys TechnologyCorp.BioVaxys Technology Corp. (www.biovaxys.com), abiopharmaceuticals company registered in British Columbia, Canada, isa clinical-stage biopharmaceutical company dedicated to improvingpatient lives with novel immunotherapies based on the DPX™immune-educating technology platform and its HapTenix© tumor cellconstruct platform, for treating cancers, infectious disease, antigendesensitization for food allergy, and other immunological diseases.Through a differentiated mechanism of action, the DPX™ platformdelivers instruction to the immune system to generate a specific,robust, and persistent immune response. The Company's clinicalstage pipeline includes maveropepimut-S (MVP-S), based on the DPX™platform, in phase IIB clinical development for advancedRelapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinumresistant Ovarian Cancer. MVP-S delivers antigenic peptides from thesurvivin family, a set of well-recognized cancer antigens commonlyoverexpressed in advanced cancers, and also delivers an innate immuneactivator and a universal CD4 T cell helper peptide. MVP-S has beenwell tolerated and has demonstrated defined clinical benefit inmultiple cancer indications as well as the activation of a targetedand sustained, survivin-specific anti-tumor immune response. BioVaxysis also developing DPX™+SurMAGE, a dual-targeted immunotherapycombining antigenic peptides for both the survivin and MAGE-A9 cancerproteins to elicit immune responses to these two distinct cancerantigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus,DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalizedimmunotherapeutic vaccine using its proprietary HapTenix©'neoantigen' tumor cell construct platform for refractivelate-stage ovarian cancer.BioVaxys common shares are listed on the CSE under thestock symbol &#34;BIOV&#34; and trade on the Frankfurt Bourse (FSE:5LB) and in the U.S. on the OTC Markets (OTCQB: BVAXF). For moreinformation, visit www.biovaxys.com andconnect with us on X and LinkedIn.ON BEHALF OF THE BOARDSigned &#34;James Passin&#34; James Passin, CEO+1 646 452 7054 Cautionary Statements RegardingForward Looking InformationThis press release includes certain&#34;forward-looking information&#34; and &#34;forward-lookingstatements&#34; (collectively &#34;forward-looking statements&#34;) within the meaning of applicable Canadian and United States securitieslegislation including the United States Private Securities LitigationReform Act of 1995. All statements, other than statements ofhistorical fact, included herein, without limitation, statementsrelating to the future operating or financial performance of theCompany, are forward looking statements. Forward-looking statementsare frequently, but not always, identified by words such as&#34;expects&#34;, &#34;anticipates&#34;, &#34;believes&#34;,&#34;intends&#34;, &#34;estimates&#34;, &#34;potential&#34;,&#34;possible&#34;, and similar expressions, or statements thatevents, conditions, or results &#34;will&#34;, &#34;may&#34;,&#34;could&#34;, or &#34;should&#34; occur or be achieved. Therecan be no assurance that such statements will prove to be accurate,and actual results and future events could differ materially fromthose expressed or implied in such forward-looking statements.These forward-looking statements reflect the beliefs,opinions and projections on the date the statements are made and arebased upon a number of assumptions and estimates, primarily theassumptions that the Company and its auditor will be able to completethe Annual Filings and that BioVaxys will be successful in developingand testing vaccines, that, while considered reasonable by theCompany, are inherently subject to significant business, economic,competitive, political and social uncertainties and contingenciesincluding, primarily but without limitation, the risk thatBioVaxys' vaccines will not prove to be effective and/ or willnot receive the required regulatory approvals. With regards toBioVaxys' business, there are a number of risks that could affectthe development of its biotechnology products, including, withoutlimitation, the need for additional capital to fund clinical trials,its lack of operating history, uncertainty about whether its productswill complete the long, complex and expensive clinical trial andregulatory approval process for approval of new drugs necessary formarketing approval, uncertainty about whether its autologous cellvaccine immunotherapy can be developed to produce safe and effectiveproducts and, if so, whether its vaccine products will be commerciallyaccepted and profitable, the expenses, delays and uncertainties andcomplications typically encountered by development stagebiopharmaceutical businesses, financial and development obligationsunder license arrangements in order to protect its rights to itsproducts and technologies, obtaining and protecting new intellectualproperty rights and avoiding infringement to third parties and theirdependence on manufacturing by third parties.The Company does not assume any obligation to updatethe forward-looking statements of beliefs, opinions, projections, orother factors, should they change, except as required by law.Investors are encouraged to read BioVaxys continuous disclosuredocuments and audited annual consolidated financial statements whichare available on SEDAR+ at www.sedarplus.ca.Copyright (c) 2026 TheNewswire - All rights reserved.</div></div>

IBBQ

PCVX

DVAX

BioVaxys Technology Corp. announced it could not file its annual financial statements by the February 28, 2026 deadline due to delays in auditing caused by changes in accounting systems. Consequently, the company applied for a management cease trade order (MCTO), which was granted on March 3, 2026, prohibiting trading by its CEO and CFO. The company expects to complete the annual filings by April 28, 2026, and will comply with alternative information guidelines during this period.

BioVaxys Announces Application for Management Cease Trade Order